Treatment options for chemotherapy-induced nausea and vomiting: Current and future

American Journal of Cancer

Volumn 2, Issue 1, 2003, Pages 15-26

  Stieler, Jens M ^a   Reichardt, Peter ^a   Riess, Hanno ^a   Oettle, Helmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CANNABINOID; CISAPRIDE; CORTICOSTEROID; DEXAMETHASONE; DOLASETRON MESILATE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; GRANISETRON; HALOPERIDOL; METHYLPREDNISOLONE; METOCLOPRAMIDE; NEUROKININ A; NEUROKININ B; NEUROPEPTIDE K; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; SEROTONIN ANTAGONIST; SUBSTANCE P; SUMATRIPTAN; TACHYKININ RECEPTOR ANTAGONIST; TETRAHYDROCANNABINOL; TROPISETRON;

ACUTE DISEASE; AKATHISIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DYSPHORIA; DYSTONIA; EUPHORIA; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SEDATION; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 0042823664     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302010-00002     Document Type: Review

References (134)

1. Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patients' perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-95
2. Uyl-de Groot CA, Wait S, Buijt I. Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. Eur J Cancer 2000; 36: 1522-35
3. Cubbedu LU. Serotonin mechanism in chemotherapy induced emesis in cancer patients. Oncology 1996; 53 Suppl. 1: 18-25
4. Bountra C, Gale JD, Gardner CJ, et al. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology 1996; 53 Suppl. 1: 102-9
5. Leslie RA. Comparative aspects of the area postrema: fine structural considerations help to determine its function. Cell Mol Neurobiol 1986; 6: 95-120
6. Kilkpatrick GJ, Jones BJ, Tyers MB. Binding of the 5-HT3 ligand (3H)GR65630 to rat area postrema, vagus nerve and the brain of several species. Eur J Pharmacol 1989; 159: 157-64
7. Carpenter DO, Briggs DB, Knox AP, et al. Excitation of area postrema neurons by transmitters, peptides and cyclic nucleotides. J Neurophysiol 1988; 59 (2): 358-69
8. Blackshaw LA, Grundy D, Scratcherd T. Vagal afferent discharge from gastric mechanoreceptors during contraction and relaxation of the ferret corpus. J Auton Nerv Syst 1987; 18: 19-24
9. Jean A, Tell F. Cellular bases for a multifunctional role of nucleus tractus solitarii neurons. In: Bianchi AL, Grelot L, Miller AD, et al., editors. Mechanisms and control of emesis. London: Colloque INSERM/John Libbey Eurotext Ltd, 1992: 85-7
10. Davison JS. Activation of vagal gastric mechanoreceptors by cholecystokinin. Proc West Pharmacol Soc 1986; 29: 363-6
11. Gershon MD, Takaki M, Tamir H, et al. The enteric neural receptor for 5-hydroxytryptamine. Experientia 1985; 41: 863-8
12. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193-230
13. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985; 55: 2303-16
14. Allan SG, Smyth JF. Small intestine mucosal toxicity of cisplatin: comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 1987; 53: 355-60
15. du Bois A, Meerpohl HG, Siebert C, et al. Excretion patterns of 5-HIAA under platinum-based chemotherapy: the role of 5-HT in drug induced emesis [abstract]. Proc Am Soc Clin Oncol 1992; 381: 11
16. Kellum JM, Albuquerque FC, Stoner MC, et al. Stroking human jejunal mucosa induces 5-HT release and Cl secretion via afferent neurons and 5-HT4 receptors. Am J Physiol 1999; 277 (3 Pt 1): G515-20
17. Lang IM. Noxious stimulation of emesis. Dig Dis Sci 1999; 44 (8 Suppl.): 58S-63S
18. Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982; 66: 1487-93
19. Cubbedu LX, Hoffmann IS, Fuenmayor NT, et al. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992; (66): 198-203
20. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999; 4: 191-6
21. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-9
22. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics; evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17 (9): 2971-94
23. Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 1999 Jul; 3 (3): 113-9
24. Sullivan JR, Leyden MJ, Bell R. Decreased cisplatin induced nausea and vomiting with chronic alcohol ingestion [letter]. N Engl J Med 1983; 309: 796
25. Koo WH, Ang PT. Role of maintenance of oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996; 7 (1): 74
26. Ossi M, Anderson E, Freeman A. 5-HT3 receptor antagonist in the control of cisplatin-induced delayed emesis. Oncology 1996; 53 Suppl. 1: 78-85
27. Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002; 10 (2): 88-95
28. Morrow GR, Lindke J, Black PM. Anticipatory nausea development in cancer patients: replication and extension of a learning model. Br J Psychol 1991; 82 (Pt 1): 61-72
29. Morrow GR. Chemotherapy related nausea and vomiting: etiology and management. CA Cancer J Clin 1989; 39: 89-104
30. Yoshikawa T, Yoshida N, Hosoki K. Involvement of dopamine D3 receptors in the area postrema in R (+)-7-OH-DPAT-induced emesis in the ferret. Eur J Pharmacol 1996; 301: 143-9
31. Yoshikawa T, Yoshida N, Oka M. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist. Br J Pharmacol 2001; 133 (2): 153-60
32. Pero RW, Olsson A, Simanaitis M, et al. Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide. Pharmacol Toxicol 1997; 80 (5): 231-9
33. Fozard JR, Mobarok Ali ATM. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 1978; 49: 109-12
34. Kris MG, Gralla RJ, Tyson L, et al. Improved control of cisplatin induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine: results of consecutive trials in 255 patients. Cancer 1985; 55: 527-34
35. Hays H. Antiemetic efficacy of metoclopramide. N Engl J Med 1986; 306: 485-6
36. Kris MG, Tyson LB, Gralla RJ, et al. Extrapyramidal reactions With high-dose metoclopramide [letter]. N Engl J Med 1983; 309: 433-4
37. Allen JC, Gralla R, Reilly L, et al. Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 1985; 3: 1136-41
38. Gebbia V, Testa A, Cannata G, et al. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. Anticancer Drugs 1996; 7 (7): 734-7
39. Megens AA, Awouters FH, Niemegeers CJ. General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine and cisapride. Arzneimittcl Forschung 1991; 41 (6): 631-4
40. Clarke DE, Craig DA, Fozard JR. The 5-HT4 receptor: naughty, but nice. Trends Pharmacol Sci 1989; 10: 385-6
41. Saller R, Hellenbrecht D. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis. Eur J Cancer Clin Oncol 1986; 22: 1199-203
42. Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol 1984; 19 Suppl. 96: 127-36
43. Bennett JR, Stanciu C. The effect of metoclopramide on gastrointestinal reflux. Postgrad Med J 1973; 49 Suppl. 4: 65-8
44. Hardy J, Daly S, McQuade B, et al. A double-blind, randomised, parallel group, multinational, multicenter study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer 2002; 10: 231-6
45. Seng KT, Tiong CE, Hiang TC. Anti-emetic effect of high-dose metoclopramide vs alizapride: a randomized crossover study. Br J Pharmacol 1994; 38 (3): 282-4
46. Munstedt K, Wunderlich I, Blauth-Eckmeyer E, et al. Does dexamethasone enhance the efficacy of alizapride in cis-platinuminduced delayed vomiting and nausea? Oncol 1998; 55 (4): 293-9
47. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7 (1): 108-14
48. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorphenazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med 1981; 305: 905-9
49. Grunberg SM, Gala KV, Lampenfeld M, et al. Comparison of the the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 1984; 2: 782-7
50. Carr BI, Blayney DW, Goldberg DA, et al. High doses of prochlorperazine for cisplatin-induced emesis: a prospective, randomized dose-response study. Cancer 1987; 60: 2165-9
51. Brogden RN, Carmine AA, Heel RC, et al. Domperidone: a review. Drugs 1982; 24(5): 360-400
52. Joss RA, Goldhirsch A, Brunner KW, et al. Sudden death in cancer patient on high-dose domperidonc [letter]. Lancet 1982; I: 1019
53. Wood CD, Kennedy RE, Graybiel A, et al. Clinical effectiveness of anti-motion sickness drugs. JAMA 1966; 198: 1155-8
54. Ladabaum U, Hasler WL. Novel approaches in the treatment of nausea and vomiting. Dig Dis 1999; 17: 125-32
55. Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone: a double-blind, randomised trial. Cancer 1987; 60: 2816-22
56. Uphouse L. Multiple serotonine receptors: too many, not enough orjust the right number? Neurosci Biobehav Rev 1997; 21 (5): 679-98
57. Hcsketh PJ. Comparative review of 5-HT3 antagonists in the treatment of acute chemotherapy-induced nausea and vomiting [review]. Cancer Invest 2000; 18 (2): 163-73
58. Walton SM. Advances in the use of the 5-HT3 receptor antagonists. Expert Opin Pharmacother 2000 Jan; 1 (2): 207-23
59. Fox-Geiman MP, Fisher SG, Kiley K, et al. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV granisetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant 2001; 7 (11): 596-603
60. De Wit R, de Boer AC, vd Linden GH, et al. Effective cross-over to granisetron after failure to ondansetron, a randomised double-blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following-high emetogenic chemotherapy. Br J Cancer 2001; 85 (8): 1099-101
61. Tsukada H, Hiruse T, Yokoyama A, et al. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 2001; 37 (18): 2398-404
62. McCallum RW. Cisapride: a new class of prokinetic agent. Am J Gastroenterol 1991; 86: 135-49
63. Fukui H, Yamamoto M, Sasaki S, et al. Possible involvement of peripheral 5-HT4 receptors in copper-sulfate-induced vomiting in dogs. Eur J Pharmacol 1994; 257: 47-52
64. Bhandari P, Andrews PL. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Eur J Pharmacol 1991; 204: 273-80
65. Hasler WL. Serotonin receptor physiology: relation to emesis. Dig Dis Sci 1999; 44 (8 Suppl.): 108-13
66. Minami M, Endo T, Tamakai H, et al. Antiemetic effects of N-3389, a newly synthesized 5-HT3 and 5-HT4 receptor antagonist, in ferrets. Eur J Pharmacol 1997; 321 (3): 333-42
67. Yamakuni H, Sawai H, Maeda Y, et al. Probable involvement of the 5-hydroxytryptamine (4) reccptor in methotrexate-induced delayed emesis in dogs. J Pharmacol Exp Ther 2000; 292 (3): 1002-7
68. Maisano R, Spadaro P, Toscano G, et al. Cisapride and dexamathasone in the prevention of delayed emesis after cisplatin administration. Support Care Cancer 2001; 9 (1): 61-4
69. Pizzo BA, Pisters KM, Miller VA, et al. Oral cisapride for the control of delayed vomiting following high-dose cisplatin. Support Care Cancer 1999; 7 (1): 44-6
70. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998; 55 (2): 173-89
71. Horikoshi K, Yokoyama T, Kishibayashi N, et al. Possible involvement of 5-HT4 receptors, in addition to 5-HAT-3 receptors, in the emesis induced by high-dose cisplatin in suncus murinus. Jpn J Pharmacol 2001; 85 (1): 70-4
72. Okada F, Torii Y, Saito H, et al. Antiemetic effects of serotonergic 5-HT1A receptor agonists in Suncus murinus. Jpn J Pharmacol 1994; 64: 109-14
73. Wolff MC, Leander JD. Effects of a 5-HT1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting. Eur J Pharmacol 1997; 340 (2-3): 217-20
74. Okada F, Saito H, Matsuki N. Blockage of motion-sickness and cisplatinum-induced cmesis by a 5-HT2 receptor agonist in suncus murinus. Br J Pharmacol 1995; 114: 931-4
75. Sam TS, Chan SW, Rudd JA, et al. Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferrct. Eur J Pahrmacol 2001; 417 (3): 231-7
76. Ioannidis JP, Hcsketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000; 18 (19): 3409-22
77. Koo WH, Ang PT. Randomized controlled study to evaluate the role of oral dexamethasone in preventing of chemotherapy-induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1995; 14: 531
78. Ohmatsu H, Eguchi K, Shinkai T, et al. A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. Jpn J Cancer Res 1994; 85: 1151-8
79. Roila F, De Angelis V, Contu A, et al. Ondansetron (OND) vs metoclopramidc (MTC) both combined with dexamethasone (DEX) in the prevention of cisplatin (CDDP)-induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1996; 15: 528
80. Roila F, Ballatori E, de Angelis V, et al. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced emesis. J Clin Oncol 1998; 16 (9): 2937-42
81. Lee B. Methylprednisolone as an antiemetic. N Engl J Med 1981; 304: 486-98
82. Jez E, Sulkes A, Ochayen L, et al. Methylprednisolone versus metoclopramide as an antiemetic treatment in patients receiving adjuvant cyclophosphamide, methothrexate, 5 fluorouracil (CMF) chemotherapy: a randomised crossover blind study. J Chemother 1989; 1: 365-8
83. Peterson C, Hursti TJ, Borjeson S, et al. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs control of delayed symptoms. Support Care Cancer 1996; 4 (6): 440-6
84. Schmidt PT, Holst JJ. Tachykinins in the regulation of gastric motility and secretion. Cell Mol Life Sci 2000; 57: 579-88
85. Rudd JA, Ngan MP, Wai MK. Inhibition of emesis by tacykinin NK1 receptor antagonists act in suncus murinus (house musk shrew). Eur J Pharmacol 1999; 366: 243-52
86. Ariumi H, Saito R, Nago S, et al. The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. Neurosci Lett 2000; 286: 123-6
87. Tattersall FD, Rycoft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996; 35: 1121-9
88. Dixon MK, Nathan NA, Hornby PJ. Immunohistochemical distribution of neurokinin 1 receptor in rat dorsal vigal complex. Peptides 1998; 19: 913-23
89. Krowicki ZK, Hornby PJ. Substance P in the dorsal motor nucleus of the vagus evokes gastric motor inhibition via neurokinin 1 receptor in rat. J Pharmacol Exp Ther 2000; 293: 214-21
90. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001; 111: 106-12
91. Stout SC, Owens MJ, Nemeroff CB. Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol 2001; 41: 877-906
92. Maubach KA, Martin K, Chicchi G, et al. Chronic substance P (NK (1)) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coerulcus. Neurosci 2002; 109 (3): 609-17
93. Bensaid M, Faucheux BA, Hirsch E, et al. Expression of tachykinin NK2 receptor RNA in human brain. Neurosci Lett 2001; 303: 25-8
94. Mileusnic D, Lee JM, Magnuson DJ, et al. Neurokinin-3 receptor distribution in rat and human brain: an immunhistological study. Neuroscience 1999; 89 (4): 1269-90
95. Lördal M, Navalesi G, Theodorsson E, et al. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokin A in small intestine. Br J Pharmacol 2001; 134: 215-23
96. Lördal M, Theodorsson E, Hellstrom PM. Tachykinins influence interdigestive rhythm and contractile strength of human intestine. Dig Dis Sci 1997; 42 (9): 1940-9
97. Horgan KJ, Eldridge KN, Carides A, et al. Differential time course of cisplatin induced emesis with a 5-HT3 antagonist or an NK1 antagonist: rationale for combination therapy [abstract 1528]. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco.
98. Campos D, Pereira JR, Reinhardt R, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist mk869, in combination with granisetron and dexamethasone of with dexamethasone alone. J Clin Oncol 2001; 19: 1759-67
99. Cocquyt V, van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 835-42
100. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomised phase II study of the neurokinin-1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999; 17 (1): 338-43
101. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective Neurokinin-1-Receptor antagonist. N Engl J Med 1999; 340 (3): 190-5
102. Reid K, Palmer JL, Wright RL, et al. Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 2000; 50 (1): 61-4
103. Einhorn L. Nabilone: an effective antiemetic agent in patients receiving chemotherapy. Cancer Treat Rev 1982; 9: 55-61
104. Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300: 1295-7
105. Gralla RJ, Tyson LB, Bordin LA, et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-terahydrocanaabinol. Cancer Treat Rep 1984; 68: 163-72
106. Piomelli D, Giuffrida A, Calignano A, et al. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21: 218-24
107. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58 (4): 315-48
108. Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced-nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 1-8
109. Kluin-Neleman JC, Neleman FA, Meuwissen OJ, et al. Delta-9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy: a double-blind cross-over trial against placebo. Vet Hum Toxicol 1979; 21: 338-40
110. Voth EA, Schwartz RH. Medical applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997; 126: 791-8
111. Harousseau JL, Zittoun R, Bonneterre J, et al. Improvement in the control of chemotherapy induced emesis with ondanstron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination [in French]. Bull Cancer 2000 Jun; 87 (6): 491-7
112. Malik IA, Khan WA, Qazilbash M, et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin: a prospective randomized trial. Am J Clin Oncol 1995; 18 (2): 170-5
113. Buzdar AU, Esparza L, Natale R, et al. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine: a placebo-controlled study. Am J Clin Oncol 1994; 17 (5): 417-21
114. Ahn MJ, Lee JS, Lee KH, et al. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. Am J Clin Oncol 1994; 17 (2): 150-6
115. Tonini M, Candura SM, Messori E, et al. Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Pharmacol Res 1995; 31 (5): 257-60
116. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 hrs following high-dose cisplatin chemotherapy. Support Care Cancer 1995; 3 (5): 307-12
117. Heron JF, Goedhals L, Jordaan JP, et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomised comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann Oncol 1994; 5 (7): 579-4
118. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomised crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9 (4): 675-8
119. Drechsler S, Bruntsch U, Eggert J, et al. Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Support Care Cancer 1997; 5(5): 387-95
120. Kris MG, Baltzer L, Pisters KM, et al. Enhancing the effectiveness of the specific serotonin antagonists: combination antiemetic therapy with dexamethasone. Cancer 1993; 72 (11 Suppl.): 3436-42
121. Eberhard LH, Morin AM, Bothner U, et al. Droperidol and 5-HT3 receptor antagonists, alone or in combination, for the prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomised controlled trials. Acta Anaesthesiol Scand 2000; 44 (10): 1252-7
122. Hesketh PJ, Gandara DR, Hesketh AM, et al. Improved control of high-dose cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. Cancer J Sci Am 1997; 3 (3): 180-3
123. Diaz-Rubio E, Martin M, Rosell R, et al. The antiemetic effect of thiethylperazine and methylprednisolone versus triethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide): a randomised, double-blind, cross-over trial. Acta Oncol 1991; 30 (3): 339-42
124. Grunberg SM, Akerley WL, Krailo MD, et al. Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest 1986; 4 (5): 379-85
125. Stephens SH, Silvey VL, Wheeler RH. A randomised, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin. Cancer 1995; 66 (3): 443-6
126. Mori K, Saito Y, Tominaga K. Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone: double-blind randomised crossover study in patients with cisplatin-induced emesis. Am J Clin Oncol 1993; 16 (4): 338-41
127. Morrow GR, Rosenthal SN. Models, mechanisms and management of anticipatory nausea and emesis. Oncology 1996; 53 Suppl. 1: 4-7
128. Redd WH, Montgomery GH, DuHamel KN. Behavioral intervention for cancer treatment side effects. J Natl Cancer Inst 2001; 93 (11): 810-23
129. Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 1997; 33 (1): 66-74
130. Hainsworth JD. The use of ondansetron in patients receiving multiple day cisplatin regimens. Semin Oncol 1992; 19: 48-52
131. The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997; 15 (1): 124-30
132. Jones AL, Lee GJ, Bosanquet N. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer 1992; 29A (1): 51-6
133. Roila F, Borschetti E, Tonato M. Predictive factors of delayed emesis in cisplatin treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone: a randomised single-blind study. Am J Clin Oncol 1991; 14: 238-42
134. 3 antagonist or an NK1 antagonist: rationale for combination therapy [abstract 1476]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18-21; Orlando (FL).